7125-76-0 Suppliers

Recommended suppliersmore

This product is a nationally controlled contraband, and the Lookchem platform doesn't provide relevant sales information.

7125-76-0 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 7125-76-0 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 7,1,2 and 5 respectively; the second part has 2 digits, 7 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 7125-76:
(6*7)+(5*1)+(4*2)+(3*5)+(2*7)+(1*6)=90
90 % 10 = 0
So 7125-76-0 is a valid CAS Registry Number.

InChI:InChI=1/C20H24N2O5/c1-22-8-7-20-12-4-5-13(21-26-10-16(23)24)19(20)27-18-15(25-2)6-3-11(17(18)20)9-14(12)22/h3,6,12,14,19H,4-5,7-10H2,1-2H3,(H,23,24)/b21-13-/t12-,14+,19-,20-/m0/s1

7125-76-0SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 19, 2017

Revision Date: Aug 19, 2017

1.Identification

1.1 GHS Product identifier

Product name	codoxime

1.2 Other means of identification

Product number	-
Other names	6-Carboxymethylen-4,4-dimethyl-2-piperidon

1.3 Recommended use of the chemical and restrictions on use

Identified uses	For industry use only.
Uses advised against	no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number	-
Service hours	Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:7125-76-0 SDS

7125-76-0Upstream product

7125-76-0Downstream Products

7125-76-0Relevant articles and documents

Reduced antinociception of opioids in rats and mice by vaccination with immunogens containing oxycodone and hydrocodone haptens

Pravetoni, Marco,Le Naour, Morgan,Tucker, Ashli M.,Harmon, Theresa M.,Hawley, Tara M.,Portoghese, Philip S.,Pentel, Paul R.

, p. 915 - 923 (2013)

Prescription opioids abuse and associated deaths are an emerging concern in the USA. Vaccination against prescription opioids may provide an alternative to pharmacotherapy. An oxycodone hapten containing a tetraglycine linker at the C6 position (6OXY(Gly)4OH) conjugated to keyhole limpet hemocyanin (KLH) has shown early proof-of-efficacy in rodents as a candidate immunogen (6OXY(Gly)4-KLH) for the treatment of oxycodone abuse. In this study, oxycodone-based and hydrocodone-based haptens were conjugated to KLH to generate immunogens that would recognize both oxycodone and hydrocodone. Vaccination with 6OXY(Gly)4-KLH increased drug binding in serum, reduced drug distribution to brain, and blunted analgesia for both oxycodone and hydrocodone. An analogous C6-linked hydrocodone vaccine blocked hydrocodone effects but less so than 6OXY(Gly)4-KLH. C8-Linked hydrocodone immunogens had only limited efficacy. Amide conjugation showed higher haptenation ratios and greater efficacy than thioether conjugation to maleimide activated KLH (mKLH). The 6OXY(Gly)4-KLH vaccine may be used for treatment of prescription opioid abuse.

COMPOSITIONS AND METHODS OF TREATING OPIOID ADDICTION

-

Paragraph 0275, (2014/04/17)

The present invention relates to conjugates and vaccine compositions for treatment of opioid addiction, and methods of use of these conjugates and compositions.

CAS

7125-76-0